Background-Ceruloplasmin (Cp) decreases nitric oxide bioavailability in blood and has been associated with cardiovascular disease (CVD) in clinical studies. We assessed the associations between Cp and incident heart failure (HF), death, and CVD in the Atherosclerosis Risk in Communities (ARIC) study. Methods and Results-Cp was measured at ARIC visit 4 (1996ARIC visit 4 ( -1998. We studied 9240 individuals without HF or CVD at ARIC visit 4 and followed them for a mean of 10.5 years. Genome-wide association study was performed to identify genetic determinants of Cp levels and evaluate their association with incident HF in ARIC participants. Cp levels (mean±SD) were higher in women versus men (335±79 versus 258±44 mg/L; P<0.0001), women on versus not on hormone-replacement therapy (398±89 versus 291±60 mg/L; P<0.0001), and African Americans versus whites (299±63 versus 293±74 mg/L; P=0.0005). After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63).
C eruloplasmin (Cp) is an enzyme synthesized in the liver that enhances low-density lipoprotein oxidation and decreases nitric oxide (NO) bioavailability through NO oxidase activity. 1, 2 NO also has an important role in cardiac contraction, and alteration in endogenous NO secretion may contribute to heart failure (HF). 3, 4 Oxidized low-density lipoprotein has a central proatherogenic role in the arterial wall, whereas decreased NO bioavailability promotes endothelial dysfunction, which also leads to atherosclerosis. 2 Cp is an acute-phase reactant, and its levels are correlated with other nonspecific inflammatory markers that are associated with cardiovascular disease (CVD) risk, such as high-sensitivity C-reactive protein (hs-CRP), leukocyte counts, and myeloperoxidase. 5, 6 Based on these observations, an association between Cp and CVD has been hypothesized.
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Several studies suggested that high Cp levels may be associated with CVD. [7] [8] [9] [10] [11] One study in white men suggested an association of Cp with incident HF. 12 To our knowledge, no studies in the literature have evaluated the association of Cp levels with HF and all-cause mortality in the overall population.
The goal of this study was to analyze the association of Cp levels with incident HF and all-cause mortality in the biracial population of the Atherosclerosis Risk in Communities (ARIC) study. We also aimed to identify the genetic variants associated with Cp levels through a genome-wide association study (GWAS) and to evaluate the associations of these genetic variants with incident HF. A secondary goal was to confirm the association of Cp levels with incident CVD events (a composite of incident CHD and stroke) in the ARIC population.
Methods

Study Population
The ARIC study is a prospective population study of CVD in 15 792 middle-aged adults recruited from 4 US communities in 1987-1989. Of the 11 656 eligible participants in visit 4 (1996-1998) , 11 484 had Cp data available. Individuals with prevalent HF (n=406), CHD (n=973), or ischemic stroke (n=268) at visit 4 and those with missing data for any variable used in the statistical models (n=523) were excluded from the study. We also excluded individuals who were not white or African American (n=27) and any African American participants at the Minnesota and Washington County field centers because of small enrollment numbers (n=31). Therefore, 9240 individuals were included in our analysis. Incident HF hospitalizations before visit 4 were determined through diagnosis codes from hospital discharges. Prevalent CHD and stroke were defined as self-reported myocardial infarction or stroke before visit 1, silent myocardial infarction (diagnosed by electrocardiographic changes), validated myocardial infarction, coronary revascularization, or stroke between visits 1 and 4. Medical history, demographic data, anthropometric data, blood pressure measurements, and fasting lipid assessments were obtained during visit 4 at the same time as the blood draw for Cp measurement. Research protocols were approved by each ARIC Field Center's institutional review board, and all participants provided written informed consent.
Outcomes
We investigated the associations of Cp with incident HF, CHD, and CVD events and all-cause mortality in the overall population and stratified by race and sex. Incident HF was defined as the first HF hospitalization or HF coded as the underlying cause of death and was noted by review of local hospital discharge lists that showed HF in any position and county death certificates. Hospitalization for HF (International Classification of Diseases [ICD]-9 code 428) was determined through diagnosis codes from hospital discharges, whereas deaths were coded as HF (ICD-9 and ICD-10, code 428 and 150). We also analyzed the association of Cp levels with incident CHD and stroke as separate outcomes. Incident CHD events included fatal CHD, definite or probable myocardial infarction, a silent myocardial infarction between examinations by electrocardiography, and coronary revascularization. Incident stroke events included only ischemic strokes, defined as validated definite or probable hospitalized embolic or thrombotic strokes. The methods of assessing incident CHD events and strokes in the ARIC study have been described previously. [13] [14] [15] Incident CVD events were a composite of incident CHD and incident ischemic stroke after ARIC visit 4. We analyzed the association of Cp with the etiology of HF (ischemic and nonischemic). Individuals who had the diagnosis of CHD (as defined above) and who also had HF (as defined above) were included in the ischemic-HF group. Individuals with the diagnosis of HF but no diagnosis of CHD were included in the nonischemic HF group. The mean follow-up time was 10.5±2.2 years for all outcomes, 10.5±2.5 years for HF, 10.8±2.2 years for allcause mortality, and 10.5±2.4 years for CVD.
Biomarker Assays
Plasma Cp levels were measured by immunoturbidimetric assay using an automated chemistry analyzer (Olympus AU400e, manufacturer Olympus Life Science Research Europa GmbH). Highly lipemic samples, which may produce excessively high-scatter signals, were avoided. The Cp turbidimetric procedure was calibrated every 14 days by using Olympus Serum Protein Multicalibrator 2 (Cat #ODR3023), which was traceable to International Federation or Clinical Chemistry Certified Reference Material (CRM)470/ Reference Preparation for Proteins in Human Serum (RPPHS). During operation of the Olympus analyzer, ≥2 levels of immunology control material were tested at least once a day. The within-run precision was <5%, and total precision was <10%. N-terminal pro-B-type natriuretic peptide (NT-proBNP) was measured by using an electrochemiluminescent immunoassay on an automated Cobas e411 analyzer (Roche Diagnostics, Indianapolis, IN) with lower limit of detection ≤5 pg/mL and coefficient of variation 3.5 to 4.7%. 16 hs-CRP levels were measured by using an immunonephelometric assay on a BNII autoanalyzer (Siemens Healthcare Diagnostics, Deerfield, IL) with a reliability coefficient of 0.99. 17, 18 Cardiac troponin T (cTnT) levels were measured by using a novel precommercial highly sensitive assay, Elecsys Troponin T (Roche Diagnostics), on an automated Cobas e411 analyzer with a lower limit of detection of 0.003 μg/L. 19
Genotyping
Genome-wide genotyping of single-nucleotide polymorphisms (SNPs) was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, CA). Study participants who refused DNA testing, unintentional duplicate samples with higher missing rates, suspected contaminated samples, samples with genotype mismatch with 47 previously genotyped SNPs, and genetic outliers based on identity-by-state statistics and EIGENSTRAT principal components analysis were excluded. Additionally, monomorphic SNPs, SNPs with no chromosome location, and SNPs with call rate <95%, minor allele frequency <1%, or Hardy-Weinberg equilibrium P<10 -6 were also excluded. In addition to SNPs genotyped using the Affymetrix 6.0 chip, among individuals of European ancestry in our study sample, genotypes were also imputed for 2.4 million autosomal SNPs identified in HapMap CEU samples. For this study, imputation genotypes were not determined in ARIC participants of African ancestry. Imputation results were summarized as an allele dosage, which was defined as the expected number of copies of the minor allele at each SNP.
For the association of the SNP with the incident HF, we used the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium database, which includes participants from ARIC study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam study. Detailed description about the genotyping in CHARGE is described elsewhere. 20
Statistical Methods
The distributions of continuous variables were evaluated to assess normality. For this analysis, we modeled Cp both as continuous and categorical variables. As a categorical variable, quartile measures were used as cut points to obtain 4 groups ( Table 1 in the online-only Data Supplement). Associations between Cp and clinical outcomes (HF, all-cause mortality, and CVD) were determined using Cox proportional-hazards modeling in both unadjusted and adjusted models. Incident HF, CHD, CVD, mortality, and stroke event rates were each calculated using time-to-event methods. For all survival analyses, the follow-up time was defined as the period from entry into the study (visit 1) to the first respective event hospitalization, death, or time an individual left the study. Additionally, we used linear terms using quartile number to obtain a P value for trend and compare any linear trend in risks with each increasing quartile. The basic model (model 1) adjusted for age (continuous), sex, race, and ARIC center as potential confounders. Model 2 included all components of model 1 and additionally adjusted for traditional cardiovascular risk factors, including total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive medication use, smoking status (current versus not current), presence of diabetes mellitus (defined as fasting blood glucose >126 mg/dL, self-reported diagnosis by a physician, or diabetes mellitus medication use), and body mass index. Because previous studies suggested that Cp levels are influenced by hormones, model 3 included all components of model 2 plus hormone-replacement therapy (HRT) use. Model 4 included all components of model 3 plus biomarkers associated with HF or CVD: hs-CRP, NT-proBNP, hs-cTnT, and estimated glomerular filtration rate (estimated by Modification of Diet in Renal Disease formula). In all models, the second, third, and fourth quartiles were compared with the first quartile.
We also performed quartile analyses stratified by race and sex. The adjustment models used were the same as those for the whole population (race was not included in race-specific analyses, and sex was not included in sex-specific analyses). In each subgroup, we additionally tested for interactions between sex and race by adding an interaction term of the 2 to each of the Cox proportional-hazards models and found no significant interaction in any of the groups.
A GWAS for serum Cp levels, both unadjusted and adjusted for age, race, sex, and ARIC center, was performed with PLINK (version 1.07) under dominant models (ie, 0, 1, or 2 risk-raising alleles). To test the association of genetic variants with clinical outcomes (HF, all-cause mortality, CVD, CHD, and stroke, separately). Cox proportional-hazards modeling was performed, producing both unadjusted and adjusted (for age, race, sex, and ARIC center) models. To assess the power of our analysis to detect the increase in risk for events per allele, we performed a power calculation using Sean Purcell's Genetic Power Calculator. 21 
Results
Cp was measured in 9240 individuals (mean age 62.6±5.6 years) and ranged from 26.9 mg/L to 852.0 mg/L. In raceadjusted models, women had significantly higher Cp levels than men (335±79 mg/L versus 258±44 mg/L; P<0.0001); and in sex-adjusted models, mean Cp levels were higher in African Americans than whites (299±63 mg/L versus 293±74 mg/L; P=0.0005). Also in race-adjusted analyses, women on HRT had significantly higher Cp levels than women not on HRT (388±89 mg/L versus 291±60 mg/L; P<0.0001). The distribution of Cp levels by sex is presented in Figure 1 , and the baseline demographic characteristics by Cp quartiles for the overall population are shown in Table 1 . Cp levels were positively correlated with hs-CRP (r=0.2; P<0.001) and negatively correlated with hs-cTnT (r=−0.12; P<0.001). No significant correlation was seen with NT-proBNP.
Associations of Cp Levels With Incident HF, Mortality, and CVD
The relations between Cp level (as a continuous variable) and HF, mortality, and CVD after adjustment for age, sex, and race are presented in Figure 2 . During a mean follow-up of 10.5 years, a total of 752 individuals were hospitalized for HF, 1275 had died, and 1234 had CVD events. Cp level was associated with HF and all-cause mortality in the model adjusted for traditional risk factors and HRT as well as in the fully adjusted model in which hs-CRP, NT-proBNP, hs-cTnT, and estimated glomerular filtration rate were added (hazard ratio [HR], 1.14 per SD; 95% confidence interval [CI], 1.04-1.24 for HF; HR, 1.12 per SD, 95% CI, 1.04-1.20 for all-cause mortality; Table  2 in the online-only Data Supplement). After adjustment for traditional risk factors and HRT, Cp was associated with CVD and stroke but not with CHD. The relations were not significant in the fully adjusted model.
For the categorical analysis, HRs are presented with the first quartile as reference ( Table 2 ). Individuals with Cp in the highest quartile had significantly higher risk for HF hospitalization than those in the lowest quartile (HR, 1.71; 95% CI, 1.33-2.17) after adjusting for traditional risk factors and HRT. The association remained significant in the fully adjusted model (HR, 1.44; 95% CI, 1.13-1.83). After adjustment for traditional risk factors, Cp was associated with both ischemic HF (HR, 1.76; 95% CI, 1.19-2.61) and non ischemic HF (HR, 1.67; 95% CI, 1.22-2.29). After adjustment for hs-cTnT, hs-CRP, and NT-proBNP, the association remained significant only for nonischemic HF (HR, 1.44; 95% CI, 1.05-1.98; Table 3 in the online-only Data Supplement). Individuals with Cp in the highest quartile also had greater all-cause mortality than those in the lowest quartile after adjusting for traditional risk factors and HRT (HR, 1.57; 95% CI, 1.30-1.89) as well as in the fully adjusted model (HR, 1.38; 95% CI, 1.11-1.63; Table 2 ). Cp was also associated with noncardiovascular death even in the most complex models (HR, 1.63; 95% CI, 1.25-2.14) but not with cardiovascular death ( Table 4 in the online-only Data Supplement). In the overall population, Cp level was associated with incident CVD after adjusting for traditional CVD risk factors (HR, 1.21; 95% CI, 1.00-1.49) but not in the fully adjusted model. Cp was not associated with CHD or stroke as separate outcomes ( Table 2) .
We also performed a subgroup analysis by race and sex (Table 5A -5D in the online-only Data Supplement). There was no interaction between Cp and sex for risk of incident HF (P=0.22). In the sex-stratified analysis, Cp was associated with HF in both women and men in the models adjusted for traditional risk factors and in the fully adjusted models (HR, 1.43; 95% CI, 1.06-1.93 for women; and HR, 1.38; 95% CI, 1.00-1.88 for men; Table 5C and 5D in the online-only Data Supplement). There was no interaction between Cp and race for risk of incident CHD (P=0.96) or HF (P=0.55). In the white subgroup, after adjustment for traditional risk factors and HRT use, Cp level in the highest quartile was significantly associated with incident HF (HR, 1.78; 95% CI, 1.32-2.40) and all-cause mortality. Higher Cp levels were also associated with CVD, CHD, and stroke. In the fully adjusted models, the associations remained significant for all outcomes except CHD ( Table 5A in the online-only Data Supplement).
GWAS for Serum Cp Levels
We next performed race-stratified GWAS in 8094 subjects in ARIC. Serum Cp levels were primarily associated with a ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HDL, high-density lipoprotein; HRT, hormone-replacement therapy; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; HTN, hypertension; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide. single locus (rs13072552) on chromosome 3, which contains the CP gene (Figure 3 ). In the race-specific analysis (Table 3) , Cp levels in TT homozygotes and heterozygotes (GT) were significantly higher than in GG homozygotes (the normal variant) in both whites and African Americans. Although the minor allele frequency was smaller in whites (0.07) than in African Americans (0.42), the impact of the allele on Cp level was higher in whites than in African Americans (respective mean increase per allele 18 mg/L and 8.5 mg/L), and the interaction between race and allele was statistically significant (P<0.0001)
Associations of rs13072552 With Incident HF
We next investigated the relation between the rs13072552 variant and HF in CHARGE. Because of differences in the impact of the SNP on Cp levels and the differences in the minor Model 1 is adjusted for age, sex, race, and Atherosclerosis Risk in Communities site. Model 2 is adjusted for all variables in model 1 plus total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive medication use, smoking status, and presence of diabetes mellitus (fasting blood glucose >126 mg/dL, self-reported diagnosis by a physician, or diabetes mellitus medication use), and body mass index. Model 3 is adjusted for all variables in model 2 plus hormone-replacement therapy use. Model 4 is adjusted for all the factors included in model 3 plus high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin T, and estimated glomerular filtration rate. Presented as hazard ratio (95% confidence interval). CHD indicates coronary heart disease; Cp, ceruloplasmin; CVD, cardiovascular disease; and HF, heart failure.
allele frequency in African Americans versus whites, we performed a race-stratified analysis. In CHARGE, 2526 incident HF events (12%) occurred in 20 926 whites participants and 466 events (16%) in 2895 African American participants. The mean follow-up was 11.5 years for whites and 13.7 years for African Americans. This genetic variant was not significantly associated with HF in whites (HR, 1.03; 95% CI, 0.92-1.15 for the presence of either 1 or 2 copies of the allele) or African Americans (HR, 0.97; 95% CI, 0.85-1.11). Among the whole ARIC study sample, each SD of Cp (79 mg/L) was associated with a 14% increase in risk for HF, and the increased HF risk per allele was 4%. In light of our observations that the impact of the SNP was only 18 mg/L in whites with a low minor allele frequency, our power calculations indicated we had only 18% power for whites to detect a 4% increase in risk for HF in CHARGE; therefore, we were underpowered to show a significant association between the SNP and incident HF.
Discussion
We investigated the association of Cp levels with incident HF hospitalization, all-cause mortality, and CVD in the biracial cohort of the ARIC study. Our study is the largest prospective study that shows that high levels of Cp, an inflammatory plasma protein, are associated with HF, death, and CVD. Plasma Cp levels are associated with a locus on chromosome 3 that contains the CP gene and are strongly influenced by race, sex, and HRT use.
Previous smaller studies have shown an association of Cp levels with CVD 5, 7, 8, 11, 22 and with HF in white men. 12 Our study extends these findings to the large, middle-aged, biracial cohort of men and women in the ARIC study. In this population, plasma Cp levels were associated with incident HF, all-cause mortality, and CVD. The strongest associations we observed were with HF and all-cause mortality; these associations persisted even after adjusting for other biomarkers known to have a role in HF prediction, such as NT-proBNP, hs-cTnT, and hs-CRP. 19 The risk for incident HF in the overall ARIC population was similar to that reported by Engström et al 12 in white men (mean±SD age 46.8±3.7 years) at high risk for CVD. Additionally, we show that the association remains significant even after adjustment for hs-CRP, NT-proBNP, and hs-cTnT. In comparison to the study by Engström et al, 12 our study is larger, biracial, and included both sexes and an older population (mean±SD age 62.6±5.7 years). We also found that Cp levels were associated with incident CVD events in the overall population after adjustment for traditional cardiovascular risk factors, but this association was not as strong as the one seen with HF and mortality and did not remain significant in the fully adjusted model. We found no association between Cp and incident CHD or stroke in the overall population. We found an association between higher Cp levels and incident CHD events in whites, which confirms the findings of Tang et al. 5 In addition, we also found that in the white subgroup in ARIC, higher Cp levels were also associated with incident stroke and incident CVD events. Studies in animals and humans suggest that Cp levels are influenced by hormones. 23, 24 Previous observations in very small numbers of patients found higher mean Cp levels in women compared with men and in women taking HRT compared with those who did not. 10 We extended these findings to the general population and also found significantly higher mean Cp levels in African Americans compared with whites.
The role of Cp in cardiovascular pathophysiology is not well described. Cp has been shown to have important oxidase activities, including the capacity to consume NO catalytically through NO oxidase activity, resulting in decreased NO bioavailability in plasma. Both in vitro and in vivo studies have shown that NO oxidase activity is decreased in plasma after Cp immunodepletion and in humans with aceruloplasminemia. 1, 25 Over the past several decades, clinical and experimental studies have provided substantial evidence that oxidative stress, defined as an excess production of reactive oxygen species relative to antioxidant defense, is enhanced in HF. [26] [27] [28] Animal studies have shown that NO and NO synthases play a key role in normal cardiac physiology. 3, 4 NO also has a protective role in the ischemic and failing heart; this protective role is mediated by several mechanisms, including the stimulation of soluble guanylyl cyclase, which leads to a decrease in the concentration of intracellular Ca 2+ and the inhibition of oxidative stress. Therefore, superoxide generated during oxidant stress may exert cytotoxic effects, both directly and through the rapid scavenging of NO and the formation of the highly reactive oxidant peroxynitrite, which is formed at diffusionlimited rates from interaction of NO with superoxide. 29 It is possible that high levels of Cp may decrease the available NO in the heart through increased NO oxidase activity, and as a result, enhanced oxidative stress causes more dysfunction, which would explain the association between higher Cp levels and incident HF. Prevention of HF is clearly an important goal not only to reduce pain suffering and death from HF but also to reduce the high cost of treatment once patients become symptomatic enough to require hospitalization. We hypothesize that the use of new biomarkers will not only help in regards to risk stratification but also may help to identify individuals for whom specific treatment strategies are indicated. Cp is an inexpensive, easy to perform automated assay that should be examined to see if therapies that target oxidative stress pathways have benefit in the subpopulation of individuals at increased risk of HF who have high levels of Cp.
One of the novel aspects of our study is that in addition to testing the association of Cp levels with incident HF, we also performed a GWAS analysis to determine whether certain SNPs are associated with the same outcome. Our GWAS identified a locus on chromosome 3 in the CP gene that controls Cp levels, rs13072552, which is the same locus found by Tang et al. 5 This SNP is intronic, and it was associated with increased Cp levels in both whites and African Americans. Although minor allele frequency was much greater in African Americans, the impact of this SNP on Cp levels was much higher in whites. When we analyzed the association of rs13072552 with incident HF, we found no significant association; however, in spite of using the CHARGE database, our power calculations suggest that we had insufficient power to rule out the possibility that this SNP is associated with incident HF and that genetically elevated levels of Cp are in the causal pathway. Much larger studies are needed to test this association.
Limitations
A limitation in our study is insufficient power in the GWAS analysis to rule out an association between rs13072552 and clinical outcomes. Another limitation of our study is that the measurements were performed at only 1 time point using frozen plasma samples.
Conclusion
Cp levels were higher in women than men and were associated with HRT use. Higher plasma Cp levels were associated with incident HF, mortality, and CVD in the overall ARIC population but not with CHD or stroke as separate outcomes. Cp levels were associated with incident HF, death, CVD, CHD, and stroke in whites. Genetic variation of rs13072552 in the CP gene was associated with plasma Cp levels but not with HF, death, CVD, CHD, or stroke in the ARIC population.
